The US FDA has approved cefepime and zidebactam (Zaynich) for the treatment of adults with complicated urinary tract infections (cUTIs), including pyelonephritis. Cefepime is a cephalosporin antibiotic, while zidebactam is a beta-lactamase inhibitor and a non-beta-lactam antibacterial agent.
Clinical evidence In a clinical trial involving 530 patients with cUTIs, cefepime-zidebactam achieved an 89.0% combined clinical cure and microbiological response rate, compared with 68.4% for meropenem. Dosage and administration Recommended dose: 3 g (cefepime 2 g and zidebactam 1 g) Administered as an intravenous infusion over 1 hour every 8 hours Treatment duration: 7 to 10 days Recommended for patients with an estimated glomerular filtration rate (eGFR) ≥60 mL/min Contraindications Hypersensitivity to any component of Zaynich or other beta-lactum antibacterial drugs Warnings and precautions…
